GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Statera BioPharma Inc (STU:7CB) » Definitions » Liabilities-to-Assets

Statera BioPharma (STU:7CB) Liabilities-to-Assets : 1.80 (As of Sep. 2022)


View and export this data going back to 2021. Start your Free Trial

What is Statera BioPharma Liabilities-to-Assets?

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Statera BioPharma's Total Liabilities for the quarter that ended in Sep. 2022 was €23.15 Mil. Statera BioPharma's Total Assets for the quarter that ended in Sep. 2022 was €12.88 Mil. Therefore, Statera BioPharma's Liabilities-to-Assets Ratio for the quarter that ended in Sep. 2022 was 1.80.


Statera BioPharma Liabilities-to-Assets Historical Data

The historical data trend for Statera BioPharma's Liabilities-to-Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Statera BioPharma Liabilities-to-Assets Chart

Statera BioPharma Annual Data
Trend Dec19 Dec20 Dec21
Liabilities-to-Assets
1,895.50 4.53 1.07

Statera BioPharma Quarterly Data
Dec19 Mar20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Liabilities-to-Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.24 1.07 1.18 1.51 1.80

Competitive Comparison of Statera BioPharma's Liabilities-to-Assets

For the Biotechnology subindustry, Statera BioPharma's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Statera BioPharma's Liabilities-to-Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Statera BioPharma's Liabilities-to-Assets distribution charts can be found below:

* The bar in red indicates where Statera BioPharma's Liabilities-to-Assets falls into.



Statera BioPharma Liabilities-to-Assets Calculation

Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.

Statera BioPharma's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2021 is calculated as:

Liabilities-to-Assets (A: Dec. 2021 )=Total Liabilities/Total Assets
=20.068/18.735
=1.07

Statera BioPharma's Liabilities-to-Assets Ratio for the quarter that ended in Sep. 2022 is calculated as

Liabilities-to-Assets (Q: Sep. 2022 )=Total Liabilities/Total Assets
=23.146/12.876
=1.80

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Statera BioPharma  (STU:7CB) Liabilities-to-Assets Explanation

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.


Statera BioPharma Liabilities-to-Assets Related Terms

Thank you for viewing the detailed overview of Statera BioPharma's Liabilities-to-Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Statera BioPharma (STU:7CB) Business Description

Traded in Other Exchanges
N/A
Address
4333 Corbett Drive, Suite 1082, Fort Collins, CO, USA, 80525
Statera BioPharma Inc is a pre-clinical and clinical biopharmaceutical company developing multiple product candidates to address unmet medical needs for use in diseases involving immune system dysfunction.

Statera BioPharma (STU:7CB) Headlines

No Headlines